Lataa...
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
OBJECTIVE: Treatment of dyslipidemia lowers cardiovascular (CV) risk. Although statin use is a cornerstone therapy, many patients are not achieving their risk-specific low-density lipoprotein cholesterol (LDL-C) goals. The proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies h...
Tallennettuna:
| Julkaisussa: | J Drug Assess |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7470150/ https://ncbi.nlm.nih.gov/pubmed/32939318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2020.1801452 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|